Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial

被引：0
|
作者：
Atkins, Michael B. [1 ]
Escudier, Bernard [2 ]
Mcdermott, David F. [3 ]
Burotto, Mauricio [4 ]
Choueiri, Toni K. [5 ,6 ]
Hammers, Hans J. [7 ]
Plimack, Elizabeth R. [8 ]
Porta, Camillo [9 ]
George, Saby [10 ]
Powles, Thomas [11 ]
Donskov, Frede [12 ,13 ]
Kollmannsberger, Christian K. [14 ]
Grimm, Marc-Oliver [15 ]
Tomita, Yoshihiko [16 ]
Rini, Brian, I [17 ]
Jiang, Ruiyun [18 ]
Federov, Viktor [18 ]
Lee, Chung-Wei [18 ]
Desilva, Heshani [18 ]
Tannir, Nizar M. [19 ]
Motzer, Robert J. [20 ]
机构：
[1] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Gustave Roussy, Villejuif, France
[3] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
[4] Bradford Hill Clin Res Ctr, Santiago, Chile
[5] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[6] Harvard Med Sch, Boston, MA USA
[7] UT Southwestern Kidney Canc Program, Dallas, TX USA
[8] Fox Chase Canc Ctr, Oreland, PA USA
[9] Univ Pavia, Pavia, Italy
[10] Roswell Pk Canc Inst, Buffalo, NY USA
[11] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, Royal Free Natl Hlth Serv Trust, London, England
[12] Univ Hosp, Cesena, Italy
[13] Southern Denmark Univ Hosp, Vejle, Denmark
[14] British Columbia Canc Agcy, Abbotsford, BC, Canada
[15] Jena Univ Hosp, Jena, Germany
[16] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[17] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[18] Bristol Myers Squibb, Moreton, England
[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[20] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
ONCOLOGIST | 2024年 / 29卷
关键词：
Nivolumab; Ipilimumab; CheckMate; 214; Advanced RCC; Favorable Risk;
D O I：
10.1093/oncolo/oyae181.026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8
引用
收藏
页码：S17 / S18
页数：2
相关论文
共 50 条
  • [41] Characterization of response to nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
    Rini, B. I.
    Tannir, N. M.
    Escudier, B.
    McDermott, D. F.
    Grimm, M-O.
    Porta, C.
    Powles, T.
    Kollmannsberger, C. K.
    Gurney, H. P.
    Tykodi, S. S.
    Harrison, M.
    Heng, D. Y. C.
    Gruenwald, V.
    Choueiri, T. K.
    Mekan, S.
    McHenry, M. B.
    Hammers, H. J.
    Motzer, R. J.
    George, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial (vol 20, pg 297, 2019)
    Cella, D.
    Grunwald, V
    Escudier, B.
    LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293
  • [43] Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.
    Tannir, Nizar M.
    Motzer, Robert J.
    Plimack, Elizabeth R.
    McDermott, David F.
    Barthelemy, Philippe
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Kollmannsberger, Christian K.
    Gurney, Howard
    Amin, Asim
    Grimm, Marc-Oliver
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Escudier, Bernard
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [44] EFFICACY OF NIVOLUMAB PLUS IPILIMUMAB IN PRIMARY TUMOR AS FIRST-LINE THERAPY IN THE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
    Kikuchi, Hiroshi
    Osawa, Takahiro
    Matsumoto, Ryuji
    Abe, Takashige
    Maruyama, Satoru
    Harabayashi, Toru
    Miyata, Haruka
    Kashiwagi, Akira
    Sazawa, Ataru
    Fukui, Riyo
    Morita, Ken
    Takeuchi, Ichiro
    Yamashita, Noboru
    Minami, Keita
    Mochizuki, Tango
    Shinohara, Nobuo
    JOURNAL OF UROLOGY, 2021, 206 : E259 - E259
  • [45] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
    Choueiri, Toni K.
    Rini, Brian I.
    Larkin, James M. G.
    Bjarnason, Georg A.
    Gravis, Gwenaelle
    Gurney, Howard
    Lee, Jae-Lyun
    Keizman, Daniel
    Haanen, John B. A. G.
    Tomita, Yoshihiko
    Uemura, Hirotsugu
    Albiges, Laurence
    Schmidinger, Manuela
    Atkins, Michael B.
    Mariani, Mariangela
    Shnaidman, Michael
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC)
    Grimm, Marc-Oliver
    Mcdermott, David F.
    Choueiri, Toni K.
    Motzer, Robert J.
    Frontera, Osvaldo Aren
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael R.
    Rodriguez-Cid, Jeronimo
    Ishii, Yuko
    Mchenry, Brent
    Rini, Brian I.
    Tannir, Nizar M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 70 - 71
  • [47] CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
    McDermott, David F.
    Choueiri, Toni K.
    Motzer, Robert J.
    Aren, Osvaldo Rudy
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael Roger
    Cid, Jeronimo Rafael Rafael Rodriguez
    Ishii, Yuko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Rini, Brian I.
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Characterization of the benefit-risk profile of nivolumab plus ipilimumab (N plus I) v sunitinib (S) for treatment-naive advanced renal cell carcinoma (aRCC; CheckMate 214).
    Tannir, Nizar M.
    Hammers, Hans J.
    Amin, Asim
    Grimm, Marc-Oliver
    Rini, Brian I.
    Mekan, Sabeen
    McHenry, M. Brent
    Kollmannsberger, Christian K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
    Vasudev, N. S.
    Ainsworth, G.
    Brown, S.
    Pickering, L.
    Waddell, T. S.
    Fife, K.
    Griffiths, R.
    Sharma, A.
    Katona, E.
    Howard, H.
    Velikova, G.
    Maraveyas, A.
    Brown, J. E.
    Venugopal, B.
    Patel, P.
    Jain, A.
    Symeonides, S.
    Nathan, P. D.
    Collinson, F.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1304 - S1305
  • [50] Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
    Choueiri, Toni K.
    Eto, Masatoshi
    Motzer, Robert
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez-Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    Powles, Thomas
    Gruenwald, Viktor
    Alekseev, Boris
    Rha, Sun Young
    Kopyltsov, Evgeny
    Kapoor, Anil
    Gordoa, Teresa Alonso
    Goh, Jeffrey C.
    Staehler, Michael
    Merchan, Jaime R.
    Xie, Ran
    Perini, Rodolfo F.
    Mody, Kalgi
    McKenzie, Jodi
    Porta, Camillo
    LANCET ONCOLOGY, 2023, 24 (03): : 228 - 238
12345